Aethlon Medical, Inc. (NASDAQ:AEMD) Partners with iBio Inc.

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. (NASDAQ:AEMD) shares fell 3.88% after announcing the formation of a large scale production collaboration agreement with iBio, Inc. (NYSE AMERICAN: IBIO). The primary goal of the collaboration is to advance the large-scale production of Galanthus nivalis agglutinin (GNA), a plant-derived lectin in Aethlon’s Hemopurifier.

Aethlon-iBio Partnership

According to iBio President, Barry Holtz, a collaboration of the two companies is an ideal combination for the delivery of new therapeutic approach for pandemic diseases and biothreats. Researchers from the two companies have already completed a feasibility study that sought to produce highly active recombinant GNA with iBio’s plant technology.

Jim Joyce, Chairman and CEO of Aethlon stated, “The production of recombinant GNA in iBio’s large-scale manufacturing facilities establishes a pathway for us to access a consistent, high-quality supply that can support our long-term clinical and commercialization objectives,”

Aethlon Hemopurifier is a first-class therapeutic device that the U.S. Food and Drugs Administration (FDA) has awarded Expedited Access Pathway for the treatment of life-threatening viruses. The biotechnology company has already validated the device’s ability to capture a broad spectrum of pandemic influenza viruses as well as mosquito-borne viruses and deadly hemorrhagic viruses.

Aethlon Medical, Inc. (NASDAQ:AEMD) is currently investigating the potential use of the Hemopurifier to reduce the presence of tumor-derived exosomes which suppresses immunity and leads to a spread of metastasis in cancer patients.

AEMD Stock Performance

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon’s stock underperformance continued in Monday’s trading session as the stock came under pressure from sellers. The stock is currently trading at multi-year lows after losing more than 70% in market value since the start of the year. The stock dropping below the $1 a share is already arousing concerns about the stock’s continued listing status in the market.

Last week Aethlon Medical, Inc. (NASDAQ:AEMD) issued a statement indicating that the NASDAQ had formally notified it that it complied with all the applicable required listing requirements. While one of the requirements is a $2.5 million stockholder equity position, the share price is also required to be above $1 a share for continued listing

Aethlon Medical, Inc. (NASDAQ:AEMD) is in need of new catalysts if it is to gain favor among investors and bounce back from current trading levels.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AEMD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

OncoSec Medical Inc. (NASDAQ:ONCS) To Make Key Presentations

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) shares gained 10.1% after the company said it will present updated clinical data on the study of ImmunoPulse IL-12, its lead oncology program. The biotechnology company will make the presentation at the upcoming 9th World Congress of Melanoma.

OncoSec Medical Inc. (NASDAQ:ONCS)

ImmunoPulse IL-12 Presentations

In addition, OncoSec Medical Inc. (NASDAQ:ONCS) is to present updated clinical data from its Phase 2 Investigator Sponsored trial in patients with unresectable metastatic melanoma. The presentation will occur at the upcoming Society for Immunotherapy of Cancer (“SITC”) 32nd Annual Meeting to be held on November 8-12, 2017,

ImmunoPulse IL-12 is a nonviral gene delivery platform designed to utilize the power of the human immune system to target and attack tumors in the body. It is currently in Phase 2 clinical monotherapy trial, for the treatment of stage three and four melanoma.

A presentation by Dr. Alain Algazi will contrast the candidate drug to its combination with pembrolizumab. The presentation will also include clinical and biomarker data from a recently completed Phase 3 monotherapy trial.

“These data, along with the emerging clinical data from the phase 2 combination study, further support the rationale for our global, open-label, registration-directed phase 2b clinical trial, PISCES/KEYNOTE-695, which we anticipate reporting initial data in mid-2018,” said CEO Punit Dhillon.

 ONCS Stock Performance

Investor confidence on OncoSec Medical Inc. (NASDAQ:ONCS) is slowly building following a string of positive news on the development of the company’s lead oncology program. The stock has bounced back from multi-year lows of below $1 a share and bullish momentum continues to grow in strength.

However, the stock is still down by more than 5% for the year after coming under pressure after rising to $1.50 share. OncoSec Medical Incorporated faces immediate resistance at $1.25 a close above which could see the stock making a push for the $1.50 mark.

OncoSec Medical Inc. (NASDAQ:ONCS) has elicited significant investor interest in the recent past as most of them take note of its robust and differentiated approach in developing cancer treatments. The company is currently merging over two decades of research and development processes to accelerate the development of its lead candidate product.

The company’s flagship product, ImmunoPulse IL-12 has already shown to deliver equal gene transmission rates while maintaining a high safety profile. OncoSec Medical Inc. (NASDAQ:ONCS) is advancing the treatment into Phase 2 trials with projected milestone for treatment approval set for 2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Endocyte, Inc. (NASDAQ:ECYT) Spikes On Prostate Cancer Deal

Endocyte, Inc. (NASDAQ:ECYT)

Endocyte, Inc. (NASDAQ:ECYT) shares gained 0.58% in Tuesday’s trading session as the stock continues to gain significant strength. Renewed investor confidence in the company follows the signing of a licensing deal for a prostate cancer candidate that represents a potential $1 billion market opportunity.

Endocyte, Inc. (NASDAQ:ECYT)

PSMA-617 License

The biopharmaceutical company stock is up by more than 300% for the month as investors continue to react to the exclusive worldwide license for PSMA-617 from ABX GmbH. The deal provides Endocyte with an advanced therapy for the treatment of prostate cancer.

Endocyte, Inc. (NASDAQ:ECYT) is currently rated as a ‘buy’ by one investment firm according to data compiled by Zack Investment Research. One firm also rates the stock as a ‘hold’.

Under the terms of the deal, Endocyte is to make a $12 million upfront payment and issue 2 million shares of its common stock. ABX is also entitled to warrants for the purchase of up to 4 million additional shares. The company could also earn up to $160 million in milestone payments and tiered royalties.

“This transaction is transformational to Endocyte, accelerating our path to commercialization. 177Lu-PSMA-617 has the potential to be the first-in-class RLT to address both bone and soft tissue disease, and it is profoundly important to the many patients suffering from mCRPC,” said Mike Sherman, President, and CEO of Endocyte.

The candidate drug is a radioligand therapeutic, designed to target the prostate-specific membrane antigen that is present in about 80% of patients suffering from metastatic castration-resistant prostate cancer. Endocyte plans to initiate a Phase 3 trial of the drug in the first half of next year with completion slated for 2020.

Endocyte Restructuring

The acquisition of worldwide rights follows the company’s June announcement that the company was focused on more valuable opportunities. A shift of focus into promising programs such as CAR T-cell SMDC adaptor platform has already come into play.

Endocyte, Inc. (NASDAQ:ECYT) is also working on EC1169 for the treatment of metastatic castration-resistant prostate cancer. It has also stopped enrollment in EC1456 trial after the program failed to achieve significant clinical activity necessary for continued advancements.

“Endocyte remains strongly committed to careful expense management and maintaining a strong balance sheet. With the exception of a very targeted effort to generate proof-of-concept data for our CAR T-cell program, we will focus our resources on the development of 177Lu-PSMA-617,” said Mr. Sherman.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ECYT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Why Volumes Exploded for DelMar Pharmaceuticals Inc (NASDAQ:DMPI)

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)

Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) are up over 80% after the biopharmaceutical company announced that the U.S. Patent and Trade Office (USPTO) issued a patent covering covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083). DMPI stock is trading around the $2.00 level after closing at $1.12 yesterday. DelMar Shares gapped up to open at $1,80 before hitting their inter-day high of $2.29. Volumes have been strong. DMPI shares have a 30-day, daily traded volume of under 150,000 but by noon today over 16.8 million shares have traded.

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)
Two day DMPI stock price chart

Delmar Pharmceuticals Patents

The newly issued patent strengthens DelMar Pharmaceuticals Inc (NASDAQ:DMPI) their intellectual property portfolio surrounding their VAL-083 manufacturing process. VAL-083 is billed by DelMar as a first-in-class DNA targeting agent that has successfully demonstrated clinical activity against a range of tumor-types in prior clinical trials sponsored by the U. S. National Cancer Institute (NCI). VAL-083 is currently protected by eight U.S. patents and eight patents outside of the U.S.

DMPI Stock

Ironically, DelMar Pharmaceuticals Inc (NASDAQ:DMPI) was downgraded by Maxim Group just one month ago – from a “Buy” to a “Hold”. DMPI stock had just made a new 52-week low of $1.05 last week. However the news surrounding the patent issuance now places the stock almost 100% off their lows. Unfortunately, long-term holders of DelMar Pharmaceutical stock are still well off their 52-week high of $6.90.

The micro-cap biopharmaceutical firm has only produced a profit for shareholders once in the past five years – in 2014. Per share losses in the other years range from (-$0.46) in 2015 to (-$1.12) in 2013. On top of that, dilution is an ongoing concern for long-term holders of the stock. In 2012 there were 3.31 million shares outstanding. By 2016 that number was reported at 10.95 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DMPI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

ITUS Corp (NASDAQ:ITUS) Explodes On Cancer Detection Patent

ITUS Corp (NASDAQ:ITUS)

Shares of ITUS Corp (NASDAQ:ITUS) surged 85.15% after the United States Patent and Trademark Office (USPTO) granted the company a patent for an early cancer detection technology. The company’s wholly-owned subsidiary Anixa Diagnostics Corporation is currently developing the technology.

ITUS Corp (NASDAQ:ITUS)
One month ITUS stock price chart

Investor Reaction

Investor reaction does not come as a surprise given what is at stake. Cancer detection and treatment is a multi-billion industry and presents ITUS Corp (NASDAQ:ITUS) a unique opportunity for growth.

The 85.15% rally helped push the stock above the $1.00 per share mark. The stock is still down by more than 60% for the year as it continues to trade in a strong downtrend. A close above the $1.30 mark could see the stock making a run for the $2.00 a share mark which serves a key resistance level. It now awaits to be seen if the new patent will continue to strengthen investor’s sentiments on the stock.

“This is the first patent to issue of several patents that we expect to issue garnering protection of our cancer detection technology. The claims of this patent were allowed in May of 2017, and now we have received the official issuance notification and patent number,” said CEO, Amit Kumar.

Cancer Detection technology

The proposed cancer detection technology utilizes flow cytometer to measure the presence and characteristics of certain circulating immune cells. ITUS Corp (NASDAQ:ITUS) is currently relying on artificial intelligence to analyze data from the immune cells, in a manner that enhances the detection of tumor in patients

The technology has successfully identified 15 types of cancer including breast, prostate, colon, and lung. The technology’s success in detecting various types of cancer is attributed to its ability to measure subtle changes in immune cells.

Itus Corporation has also started to perform additional tests in a bid to evaluate the technology’s ability to detect benign conditions that may exist in patients. The company has since renewed its collaboration with the Wistar Institute for the development of the cancer detection technology. The two have worked together over the last two years.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ITUS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Atossa Genetics Inc. (NASDAQ:ATOS) Reports Topline Trial Results

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) slumped 11.95% after announcing preliminary results from a Phase 1 study of its novel treatment for  breast cancer, Endoxifen.  Thursday’s sell-off came as a surprise given that it came after positive news. The stock has also been on an impressive run since the start of the month.

The stock is currently trading in a $0.54 – $0.93 trading range after gapping lower in March. It faces immediate resistance at the $1.00 a share mark above which it could rise to the $1.50.

Atossa Genetics Inc. (NASDAQ:ATOS)
One month ATOS stock price chart

Endoxifen Phase 1 Results

The clinical stage pharmaceutical company says its novel treatment for breast cancer, Endoxifen, was well tolerated at all dose levels, during the phase 1 trial. The treatment tropical formulation did not trigger any significant safety signals or adverse events. The top line results thus demonstrated its suitability for further clinical development.

“Based on these positive preliminary results, we are advancing our topical Endoxifen into Phase 2 studies,” commented Dr. Steven C. Quay, CEO, and President.  “We look forward to announcing the results from the oral arm of our Phase 1 study in the coming 30 to 60 days,” continued Dr. Quay.

Atossa Genetics Inc. (NASDAQ:ATOS) Endoxifen is an active metabolite of Tamoxifen, which is an FDA approved drug for preventing breast cancer. According to the company a topical formulation of the drug could help combat breast density, which is an independent breast cancer risk.

Endoxifen Edge

Tamoxifen has, to date, been used to prevent new and recurrent forms of breast cancers. However, its benefits-cost ratio has always raised concerns. Only 2% of women at a high risk of developing breast cancer currently use the formulation. The risk or actual side effects associated with the treatment has always been a big concern for patients and physicians.

Taking into consideration the number of women who are at a high risk of developing breast cancer, Atossa Genetics Inc. (NASDAQ:ATOS) could generate up to $1 billion in sales on the approval of its topical formulation Endoxifen.

Separately, Atossa Genetics Inc. (NASDAQ:ATOS) did not generate any revenue for the three and six months ended June 30, 2017. Total operating expenses for the three and six months totaled $1.9 million and $3.6 million respectively. During the quarter, the company completed a capital raise of $4.4 million to be use d on the clinical development of Endoxifen development as well as for working capital purposes.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) Unveils Cannabis-Cancer Genetics Lab

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX)

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) jumped 8.76% in Monday’s trading session after announcing the establishment of a human cannabis-cancer genetics lab that will offer personalized cancer diagnostics. The lab will develop diagnostic tools based on one’s human genome as well as tumor genetics and cannabinoids.

OTCMKTS:CNBX
Daily Candle Bar Graph $CNBX

The company has appointed Dr. Moran Grinberg to lead the genetic research team in the wake of the establishment of the cannabis-cancer genetics lab. Moran joins the company with vast experience in clinical pharmacology.

“Our mission is to commercialize a wide range of diagnostic tools that incorporate novel technologies to retrieve better outcomes of cannabinoid treatments. Understanding the genetics of cancer-cannabinoids relations complements our CTC cell count and drug sensitivity capabilities,” said Eyal Ballan, Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) CTO.

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is a biotechnology company focused on the development and licensing of cannabinoid-based treatments and therapies. The company’s research and development operations are based in Israel and are dedicated to the development of Personalized Anti-Cancer and Palliative treatments. Cannabics utilizes advanced screening systems and personalized bioinformatics tools to come up with personalized natural therapies for cancer.

SIMFO GmbH Collaboration

The company is fresh from signing a collaboration agreement with SIMFO GmbH – a world leader in cancer diagnostics. Under the terms of the agreement, Cannabics Pharmaceuticals Inc. (OTCMKTS:CNBX) is to become the exclusive global provider of the SIMFO’s CTC diagnostics. Mr. Ballan expects the collaboration to pave way for the development of effective natural anticancer therapy.

The diagnostics in question include a count of circulating tumor cells as well as drug sensitivity tests of different cannabinoids. SIMFO is currently utilizing Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) cannabinoid formulations as part of preclinical studies on cannabinoid antitumor activity and drug development.

Positive CTC Test Results

Last month, Cannabics received positive results from screening necrosis from cancer patients treated with its cannabinoids CBD and CBDA. The topline results affirm the company’s previously calculated data with regards to anti-tumor activity. The study results also indicate that Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) proprietary technology can be relied upon in providing supportive data for personalized treatments.

“The screening of CTCs treated with specific cannabinoids and CTC cell count of patients treated with cannabinoids produces an invaluable body of data in our search for effective anti-tumor treatment,” said Mr. Ballan.

Cannabics Pharmaceuticals Inc. (OTCMKTS:CNBX) recently raised $3 million that it plans to use to accelerate the development of a platform for personalized treatments with cannabis. The company plans to expand collaborations with biotech companies in a bid to harness new technologies for examining anti-tumor properties in its R&D lab.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CNBX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Is Delcath Systems, Inc. (NASDAQ:DCTH) A Buy Or A Sell?

Is Delcath Systems, Inc. (NASDAQ:DCTH)

Yesterday, shares of Delcath Systems, Inc. (NASDAQ:DCTH) rallied by 27.8% to end the day at $0.18. Regulatory approvals and commercial progress in Europe for the company’s proprietary products continues to strengthen investor’s sentiments on the stock. Fueling demand for DCTH shares is talk that the company remains undervalued at current trading levels.

Delcath Systems, Inc. (NASDAQ:DCTH)
Candle graph of Decalth share pricing

Liver Cancer Treatment Focus

Delcath Systems, Inc. (NASDAQ:DCTH) is a medical device company with great interest in the treatment of various types of cancers. The company boasts of proprietary medical technologies that are currently being used to deliver high dose chemotherapy to the liver. Its lead product is Melphalan Hydrochloride used in combination with the Delcath Hepatic Delivery System.

Delcath Systems, Inc. (NASDAQ:DCTH) technology targets a wide variety of cancers that affect the liver. Nearly 700,000 people are diagnosed with liver cancer every year presenting a target market worth about $700 million in revenues.

Chemosat Treatment Factor

Delcath Systems, Inc. (NASDAQ:DCTH) has had its share of challenges on the clinical trial front as its percutaneous hepatic perfusion system failed to meet FDA threshold for approval. However, things are starting to look up after the company posted positive results for patients who received CHEMOSAT treatment for metastatic melanoma.

Impressive sales of the CHEMOSAT delivery system continues to affirm talk why Delcath Systems remains an exciting pick at current trading levels. Expansion in Europe has allowed the company to complete over 250 treatments on the road to validating its effectiveness.

Immediate Risks

In addition, the company is also in the process of determining the safety and efficacy of its proprietary technology in a number of ongoing clinical trials. One of the trials is targeting Ocular Melanoma as well as Hepatocellular carcinoma. The release of FOCUS Phase 3 interim safety analysis could have a significant impact on the stock price.

A major concern with Delcath Systems, Inc. (NASDAQ:DCTH) stock is the fact that it has lost a significant amount of value over the past few years. The NASDAQ Capital Market is poised to rule on its exchange listing on August 14, 2017 as the stock price has gone below the $1 a share minimum bid requirement.

The management could seek a 180-day extension to allow it sort out the mess. The company may pursue a reverse stock split to shore up the share price.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DCTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Moleculin Biotech Inc (NASDAQ:MBRX) Announces Scientific Support For Research Endeavor At Mayo Clinic

Moleculin Biotech Inc (NASDAQ:MBRX)

Moleculin Biotech Inc (NASDAQ:MBRX) announced entering into an agreement with a physician at the Mayo Clinic to perform additional research on Moleculin’s WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. Moleculin Biotech is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates.

 Mayo Clinic physician-scientists requested, and Moleculin Biotech Inc (NASDAQ:MBRX) agreed, to supply them with WP1066 for preclinical testing for the potential treatment of pediatric Diffuse Intrinsic Pontine Gliomas (DIPG), a rare and very aggressive form of brain tumor.

Mayo Clinic studies have suggested that DIPG may be particularly sensitive to the inhibition of the activated form of a cell-signaling protein called STAT3, a primary target of WP1066, and their preliminary studies have demonstrated significant anti-tumor activity of WP1066 in DIPG in vitro and in vivo tumor models.

In a statement, Moleculin Biotech Inc (NASDAQ:MBRX) Chairman and CEO, Walter Klemp, said they are thrilled to work with The Mayo Clinic in exploring the treatment potential of WP1066in in treating DIPG. He added that this should make it easier to secure an IND to study WP1066 for the treatment of adult brain tumors.

In other news, Moleculin Biotech Inc (NASDAQ:MBRX) has announced the discovery of a metabolic inhibitor with the potential to treat pancreatic cancer. Klemp announced that the company has received a lot of attention from the scientific and medical community following the company’s glucose decoy technology as a potential means of killing tumors by exploiting their hyper-dependence on glycolysis for energy production. He added that during the pre-clinical testing, the company’s WP1234 has shown improved drug characteristics compared to WP1122 and greater ability to kill pancreatic cancer cell lines when compared with traditional inhibitors of glycolysis. Klemp said that the discovery makes WP1234 a promising solution to kill pancreatic cancer which is known to survive in reduced oxygen environment.

According to Mr. Klemp, any small gain made in treating pancreatic cancer will make a significant gain in the medical field owing to the fact that the disease is largely regarded as untreatable. WP1234 works by improving on known inhibitors for glycolysis by increasing drug circulation time, which in turn increases the potential for drug uptake by destruction of tumor cells. Mr. Klemp said the discovery is a result of his company’s collaboration with M.D. Anderson Cancer Center.

During the Wednesday session, the stock of Moleculin Biotech Inc (NASDAQ:MBRX) reported a +17.31% or +$0.021 to close the session at $0.145.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MBRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) Rallies On High Implied Volatility

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) stock continues to experience high implied volatility in the options market which is sometimes an indication that a major move, up or down, may be in the cards. The direction of the spike is the big puzzle given that the biopharmaceutical company is fresh from posting a wider than expected first quarter net loss.

Q1 Financial Results

For the first three months of the year, the Canadian-based developer of novel pharmaceutical therapies says it generated a net (-$4.1) million loss in revenues compared to a net (-$3.7) million loss in the previous year – the wider loss was attributed to lower net finance income.

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) revenues in the quarter totaled $261,000, an improvement from revenues of $242,000 generated in the same period last year. The increase has been attributed to the amortization of upfront payments received in connection with one of the company’s licensing agreements for Zoptrex.

Research and development expenses in Q1 2017 dropped to $2.5 million from $3.7 million. Aeterna attributes the decline to lower third-party costs for Zoptrex given that the company had already completed clinical trials in the quarter. General and administrative expenses remained stable in the quarter, coming in at $1.9 million.

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) Net Finance income in the quarter dropped by more than half to $1.5 million from $3.3 million. The decrease was caused by a change in fair value in connection with warrant liabilities. The company exited the quarter with $17.8 million in cash and cash equivalents – a drop from $22 million as of December 31, 2016.

Clinical Trial Setback

The biopharmaceutical company says it has suffered a major setback on the development of Zoptrex as a novel treatment for women struggling with recurrent or metastatic endometrial cancer. The drug failed to achieve its primary endpoint of increase in the median period of overall survival in a Phase 3 study. The study results mean the company cannot pursue regulatory approval.

“Based on this outcome, we do not anticipate conducting clinical trials of Zoptrex™ with respect to any other indications.” Regarding the company’s plans Mr. Dodd, CEO, continued, “Our focus has now shifted entirely to filing our new drug application (“NDA”) for Macrilen™ and, if the product is approved, to its commercial launch as soon as possible. We will also optimize our resources to be consistent with our focus on Macrilen™-related efforts,” said CEO, David A. Dodd.

A quarterly net loss and disappointmenting Zoptrex trials raises serious questions about the direction of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares given the high implied volatility in the market.

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) was up by 22.92% in Friday trading session ending the week at $1.18 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.